U.S. Markets closed

WuXi AppTec Co., Ltd. (603259.SS)

Shanghai - Shanghai Delayed Price. Currency in CNY
Add to watchlist
153.20-0.80 (-0.52%)
At close: 3:00PM CST
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close149.98
Open148.00
Bid153.18 x 0
Ask153.19 x 0
Day's Range148.00 - 154.50
52 Week Range67.69 - 188.28
Volume16,620,191
Avg. Volume20,225,897
Market Cap373.734B
Beta (5Y Monthly)0.87
PE Ratio (TTM)88.00
EPS (TTM)1.74
Earnings DateApr 29, 2021
Forward Dividend & Yield0.24 (0.15%)
Ex-Dividend DateJun 04, 2020
1y Target Est102.86
  • WuXi AppTec Reports Record First-Quarter 2021 Results
    PR Newswire

    WuXi AppTec Reports Record First-Quarter 2021 Results

    WuXi AppTec Co., Ltd. (stock code: 603259.SH / 2359.HK), a company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients, announces its unaudited financial results for the First-Quarter of 2021 ("Reporting Period").

  • PR Newswire

    WuXi AppTec Reports Strong 2020 Annual Results

    WuXi AppTec (stock code: 603259.SH / 2359.HK), a company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients, announces its audited annual results for the year ended December 31, 2020 ("Reporting Period").

  • WuXi AppTec Completes Acquisition of OXGENE to Further Strengthen Cell and Gene Therapy Service Offerings for Global Customers
    PR Newswire

    WuXi AppTec Completes Acquisition of OXGENE to Further Strengthen Cell and Gene Therapy Service Offerings for Global Customers

    WuXi AppTec, a leading global provider of R&D- and manufacturing-enabling services in the pharmaceutical, biotechnology and medical device industries, today announced that it has completed the acquisition of OXGENE, a pioneering United Kingdom-based contract research and development organization that designs and develops scalable gene therapy technologies. This acquisition enables WuXi AppTec to offer its customers end-to-end support in the creation and development of cutting-edge cell and gene therapies for patients in need worldwide.